Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)

被引：0

作者：

Zhan, L. J. ^{[1
]}

Barghout, S. ^{[1
]}

Raptis, S. ^{[1
]}

Al-Agha, F. ^{[1
]}

Popovacki, A. ^{[2
]}

Esfahanian, N. ^{[1
]}

Kasymjanova, G. ^{[3
]}

Proulx-Rocray, F. ^{[4
]}

Chan, S. ^{[5
]}

Richardson, M. ^{[6
]}

Brown, M. C.

Patel, D.

Dean, M. L. ^{[7
]}

Navani, V. ^{[7
]}

Moore, E.

Carvery, L. ^{[2
]}

Yan, E.

Cleary-Gosine, J. ^{[2
]}

Gibson, A. J. ^{[7
]}

Hubley, L. ^{[2
]}

Balaratnam, K. ^{[1
]}

Ngo, T. ^{[2
]}

Gill, A. ^{[9
]}

Black, M. ^{[10
]}

Sacher, A. ^{[1
]}

Bradbury, P. A. ^{[1
]}

Shepherd, F. ^{[1
]}

Leighl, N. ^{[1
]}

Cheema, P. ^{[9
]}

Kuruvilla, S. ^{[10
]}

Agulnik, J. ^{[3
]}

Banerji, S. ^{[8
]}

Juergens, R. ^{[5
]}

Blais, N.

Cheung, W. ^{[7
]}

Wheatley-Price, P. ^{[6
]}

Liu, G. ^{[1
]}

Snow, S. ^{[2
]}

机构：

[1] UHN, Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] QEII Hlth Sci Ctr, Halifax, NS, Canada

[3] Jewish Gen Hosp, Montreal, PQ, Canada

[4] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[5] Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada

[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] CancerCare Manitoba Res Inst, Winnipeg, MB, Canada

[9] William Osler Hlth Syst, Brampton Civic Hosp, Brampton, ON, Canada

[10] London Hlth Sci Ctr, London, ON, Canada

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

KRAS G12C; Advanced NSCLC; Real-World Data;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP12.03-02

引用

页码：S680 / S680

页数：1

共 50 条

[41] Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+Treatment of KRAS G12cMutated Advanced NSCLC
Johnson, M. L.
Younan, D.
Kent, S.
Balasubramanian, A.
Mesa-Frias, M.
Stollenwerk, B.
Sylvester, B. E.
Mehta, B.
Chia, V.
Brookhart, M. A.
Spira, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S353 - S354
[42] Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
Cristina Julian
Navdeep Pal
Anda Gershon
Marie Evangelista
Hans Purkey
Peter Lambert
Zhen Shi
Qing Zhang
BMC Cancer, 23
[43] United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review
Julve, M.
Kennedy, O.
Lindsay, C.
Walters-Davies, R.
Button, M. R.
Steele, N.
McGeogh, A.
Georgiou, A.
Goranov, B.
Farrugia, D.
Gorf, L.
Remer, M.
Shah, R.
Baijal, S.
Gennatas, S.
Geldart, T.
Daniels, E.
Watts, L.
Greystoke, A.
Newsom-Davis, T.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1061 - S1062
[44] Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
Gray, Jhanelle E.
Hsu, Hil
Younan, Diana
Suri, Gaurav
Chia, Victoria
Spira, Alexander
Johnson, Melissa
LUNG CANCER, 2023, 181
[45] Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Reale, M. L.
Passiglia, F.
Brambilla, M.
Pasello, G.
Minuti, G.
Bulotta, A.
Pizzutilo, P.
Sini, C.
Costa, J.
Roca, E.
Bria, E.
Pilotto, S.
Genova, C.
Metro, G.
Citarella, F.
Bordi, P.
Russo, A.
Chiari, R.
Andrikou, K.
Novello, S.
ANNALS OF ONCOLOGY, 2023, 34
[46] Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database
Jimenez-Zepeda, Victor H.
Venner, Christopher
McCurdy, Arleigh
Masih-Khan, Esther
Atenafu, Eshetu G.
Sebag, Michael
Stakiw, Julie
Song, Kevin
LeBlanc, Richard
Reiman, Tony
Louzada, Martha
Kotb, Rami
Gul, Engin
Reece, Donna
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 532 - 541
[47] IMPACT OF DISEASE PROGRESSION ON PATIENT REPORTED OUTCOMES IN ADVANCED NSCLC: EVIDENCE FROM PATIENTS TREATED IN REAL WORLD COMMUNITY ONCOLOGY SETTINGS
Walker, M. S.
Wong, W.
Ravelo, A.
Hazard, S.
Miller, P. J.
Schwartzberg, L.
VALUE IN HEALTH, 2016, 19 (03) : A160 - A160
[48] Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort.
Heist, Rebecca Suk
Yu, Junhua
Donderici, Elifnur Yay
Zhang, Nicole
Espenschied, Carin R.
Lang, Kathryn
Korytowsky, Beata
Chi, Andrew S.
Christensen, James G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study
Furubayashi, Nobuki
Morokuma, Futoshi
Tomoda, Toshihisa
Hori, Yoshifumi
Negishi, Takahito
Miura, Akihiro
Komori, Hiroki
Kuroiwa, Kentaro
Nakamura, Motonobu
ANTICANCER RESEARCH, 2022, 42 (03) : 1571 - 1577
[50] KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study
Frost, Matilde Grupe
Jensen, Kristoffer Jarlov
Gotfredsen, Ditte Resendal
Sorensen, Anne Mette Skov
Ankarfeldt, Mikkel Zollner
Louie, Karly S.
Sroczynski, Nicholas
Jakobsen, Erik
Andersen, Jon Lykkegaard
Jimenez-Solem, Espen
Petersen, Tonny Studsgaard
LUNG CANCER, 2023, 178 : 172 - 182

← 1 2 3 4 5 →